Top

BMC Cancer

Published in:

Open Access 01-12-2024 | Pancreatic Cancer | Research

Heterogeneous changes in gut and tumor microbiota in patients with pancreatic cancer: insights from clinical evidence

Authors: Feng Zhao, Anli Chen, Xiaotian Wu, Xiangyu Deng, Jiali Yang, Jianjiang Xue

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Pancreatic cancer is the foremost contributor to cancer-related deaths globally, and its prevalence continues to rise annually. Nevertheless, the underlying mechanisms behind its development remain unclear and necessitate comprehensive investigation.

Methods

In this study, a total of 29 fresh stool samples were collected from patients diagnosed with pancreatic cancer. The gut microbial data of healthy controls were obtained from the SRA database (SRA data number: SRP150089). Additionally, 28 serum samples and diseased tissues were collected from 14 patients with confirmed pancreatic cancer and 14 patients with chronic pancreatitis. Informed consent was obtained from both groups of patients. Microbial sequencing was performed using 16s rRNA.

Results

The results showed that compared with healthy controls, the species abundance index of intestinal flora in patients with pancreatic cancer was increased (P < 0.05), and the number of beneficial bacteria at the genus level was reduced (P < 0.05). Compared with patients with chronic pancreatitis, the expression levels of CA242 and CA199 in the serum of patients with pancreatic cancer were increased (P < 0.05). The bacterial richness index of tumor microorganisms in patients with pancreatic cancer increased, while the diversity index decreased(P < 0.05). Furthermore, there was a change in the species composition at the genus level. Additionally, the expression level of CA242 was found to be significantly positively correlated with the relative abundance of Acinetobacter(P < 0.05).

Conclusion

Over all, the expression levels of serum tumor markers CA242 and CA19-9 in patients with pancreatic cancer are increased, while the beneficial bacteria in the intestine and tumor microenvironment are reduced and pathogenic bacteria are increased. Acinetobacter is a specific bacterial genus highly expressed in pancreatic cancer tissue.

Available only for authorised users

Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.CrossRefPubMed

Rahib L, Wehner MR, Matrisian LM, et al. Estimated projection of US Cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708. https://doi.org/10.1001/jamanetworkopen.2021.4708.CrossRefPubMedPubMedCentral

Gui JC, Yan WL, Liu XD, et al. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. Clin Exp Med. 2014;14(2):225–33. https://doi.org/10.1007/s10238-013-0234-9.CrossRefPubMed

Scara S, Bottoni P, Scatena R, et al. CA 19– 9: biochemical and clinical aspects. Adv Cancer Biomarkers: Biochem Clin Crit Revision. 2015;867:247–60. https://doi.org/10.1007/978-94-017-7215-015.CrossRef

Dou HQ, Sun GR, Zhang LJ, et al. CA242 as a biomarker for pancreatic cancer and other diseases. Prog Mol Biol Transl. 2019;162:229–39. https://doi.org/10.1016/bs.pmbts.2018.12.007.CrossRef

Kuusela P, Haglund C, Roberts PJ, et al. Comparison of a new tumour marker CA 242 with CA 19– 9, CA 50 and carci noembryonic antigen (CEA) in digestive tract diseases. Br J Cancer. 1991;63(4):636–40. https://doi.org/10.1038/bjc.1991.146.CrossRefPubMedPubMedCentral

Binda C, Gibiino G, Sbrancia M, et al. Microbiota in the natural history of pancreatic Cancer: from Predispos ition to Therapy. Cancers. 2022;15(1):1. https://doi.org/10.3390/cancers15010001.CrossRefPubMedPubMedCentral

Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomar kers for early hepatocellular carcinoma. Gut. 2018;68(6):1014–23. https://doi.org/10.1136/gutjnl-2017-315084.CrossRefPubMed

Mozaffari SA, Salehi A, Mousavi E, et al. SARS-CoV-2-associated gut microbiome alteration; a new contributor to colorectal cancer pathogenesis. Pathol Res Pract. 2022;239:154131. https://doi.org/10.1016/j.prp.2022.154131.CrossRefPubMedPubMedCentral

10.

Mendez R, Kesh K, Arora N, et al. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer. Carcinogenesis. 2020;41(5):561–70. https://doi.org/10.1093/carcin/bgz116.CrossRefPubMed

11.

Ren Z, Jiang J, Xie H, et al. Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget. 2017;8(56):95176–91. https://doi.org/10.18632/oncotarget.18820.CrossRefPubMedPubMedCentral

12.

Kohi S, Macgregor-Das A, Dbouk M. Alterations in the duodenal fluid microbiome of patients with pancreatic Cancer. Clin Gastroenterol Hepatol. 2022;20(2):e196–227. https://doi.org/10.1016/j.cgh.2020.11.006.CrossRefPubMed

13.

Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357(6356):1156–60. https://doi.org/10.1126/science.aah5043.CrossRefPubMedPubMedCentral

14.

Riquelme E, Zhang Y, Zhang L, et al. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer outcomes. Cell. 2019;178(4):795–e806712. https://doi.org/10.1016/j.cell.2019.07.008.CrossRefPubMedPubMedCentral

15.

Chen S, Zhou Y, Chen Y, et al. FASTP: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884. https://doi.org/10.1093/bioinformatics/bty560.CrossRefPubMedPubMedCentral

16.

Magoc T, Salzberg SL, et al. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011;27(21):2957–63. https://doi.org/10.1093/bioinformatics/btr507.CrossRefPubMedPubMedCentral

17.

Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013;10(10):996–8. https://doi.org/10.1038/nmeth.2604.CrossRefPubMed

18.

Wang Q, Garrity GM, Tiedje JM, et al. Naive bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73(16):5261–7. https://doi.org/10.1128/AEM.00062-07.CrossRefPubMedPubMedCentral

19.

Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75(23):7537–41. https://doi.org/10.1128/AEM.01541-09.CrossRefPubMedPubMedCentral

20.

Lawley B, Tannock GW. Analysis of 16S rRNA gene amplicon sequences using the QIIME Software Package. Methods Mol Biol. 2017;1537:153–63. https://doi.org/10.1007/978-1-4939-6685-1_9.CrossRefPubMed

21.

Ge L, Pan B, Song F, et al. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. BMJ Open. 2017;7(12):e018175. https://doi.org/10.1053/j.gastro.2020.12.039.CrossRefPubMedPubMedCentral

22.

Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31(2):164–9. https://doi.org/10.1016/j.ejso.2004.09.007.CrossRefPubMed

23.

Kaur S, Jain M, Batra SK. Liquid biopsy for identification of high-risk cystic lesions of Pancre as. Gastroenterology. 2021;160(4):1016–8. https://doi.org/10.1053/j.gastro.2020.12.039.CrossRefPubMed

24.

Han J, Li Q, Chen Y, et al. Recent metabolomics analysis in Tumor Metabolism Reprogramming. Front Mol Biosci. 2024;8:763902. https://doi.org/10.3389/fmolb.2021.763902.CrossRef

25.

Newsome R, Jobin C. Finding clues in unexpected places: detection of pancreatic cancer thr ough the faecal microbiome. Gut. 2022;71(7):1247–8. https://doi.org/10.1136/gutjnl-2021-326710.CrossRefPubMed

26.

Hashimoto S, Tochio T, Funasaka K, et al. Changes in intestinal bacteria and imbalances of metabolites induced in the intestines of pancreatic ductal adenocarcinoma patients in a Japanese population: a preliminary result. Scand J Gastroenterol. 2023;58(2):193–8. https://doi.org/10.1080/00365521.2022.2114812.CrossRefPubMed

27.

Feng L, Zhang W, Shen Q, et al. Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome. J Cachexia Sarcopenia Muscle. 2021;12(6):1553–69. https://doi.org/10.1002/jcsm.12798.CrossRefPubMedPubMedCentral

28.

Pan LL, Li BB, Pan XH, et al. Gut microbiota in pancreatic diseases: possible new therapeutic strategies. Acta Pharmacol Sin. 2021;42(7):1027–39. https://doi.org/10.1038/s41401-020-00532-0.CrossRefPubMed

29.

Wang C, Li W, Wang H, et al. Saccharomyces boulardii alleviates ulcerative colitis carcinogenesis i n mice by reducing TNF-α and IL-6 levels and functions and by rebalanc ing intestinal microbiota. BMC Microbiol. 2019;19:1–12. https://doi.org/10.1186/s12866-019-1610-8.CrossRef

30.

Doocey CM, Finn K, Murphy C, et al. The impact of the human microbiome in tumorigenesis, cancer progression, and biotherapeutic development. BMC Microbiol. 2022;22(1):53. https://doi.org/10.1186/s12866-022-02465-6.CrossRefPubMedPubMedCentral

31.

van den Bogert B, Meijerink M, Zoetendal EG, et al. Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota. PLoS ONE. 2014;9(12):e114277. https://doi.org/10.1371/journal.pone.0114277.CrossRefPubMedPubMedCentral

32.

Zhou Q, Tao X, Xia S, et al. T lymphocytes: a promising immunotherapeutic target for pancreatitis and pancreatic Cancer? Front Oncol. 2020;10:382. https://doi.org/10.3389/fonc.2020.00382.CrossRefPubMedPubMedCentral

33.

Kandikattu HK, Venkateshaiah SU, Mishra A. Chronic pancreatitis and the development of pancreatic Cancer. Endocr Metab Immune Disord Drug Targets. 2020;20(8):1182–210. https://doi.org/10.2174/1871530320666200423095700.CrossRefPubMedPubMedCentral

34.

Sethi V, Kurtom S, Tarique M, Lavania S, et al. Gut microbiota promotes Tumor Growth in mice by modulating Immune Response. Gastroenterology. 2018;155(1):33–e3736. https://doi.org/10.1053/j.gastro.2018.04.001.CrossRefPubMed

35.

Mitsuhashi K, Nosho K, Sukawa Y, et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget. 2015;6(9):7209–20. https://doi.org/10.18632/oncotarget.3109.CrossRefPubMedPubMedCentral

36.

Maekawa T, Fukaya R, Takamatsu S, et al. Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. Biochem Biophys Res Commun. 2018;506(4):962–9. https://doi.org/10.1016/j.bbrc.2018.10.169.CrossRefPubMed

37.

Tofalo R, Cocchi S, Suzzi G, Polyamines, Microbiota G. Front Nutr. 2019;6:16. https://doi.org/10.3389/fnut.2019.00016.CrossRefPubMedPubMedCentral

38.

Sammallahti H, Kokkola A, Rezasoltani S, et al. Microbiota alterations and their association with oncogenomic changes in pancreatic Cancer patients. Int J Mol Sci. 2021;22(23):12978. https://doi.org/10.3390/ijms222312978.CrossRefPubMedPubMedCentral

39.

Casero RA Jr., Murray Stewart T, Pegg AE. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer. 2018;18(11):681–95. https://doi.org/10.1038/s41568-018-0050-3.CrossRefPubMedPubMedCentral

40.

Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic Cancer Microbiome promotes oncogenesis by induction of Innate and Adaptive Immune suppression. Cancer Discov. 2018;8(4):403–16. https://doi.org/10.1158/2159-8290.CD-17-1134.CrossRefPubMedPubMedCentral

41.

Guo W, Zhang Y, Guo S, et al. Tumor microbiome contributes to an aggressive phenotype in the basal-like subtype of pancreatic cancer. Commun Biol. 2021;4(1):1019. https://doi.org/10.1038/s42003-021-02557-5.CrossRefPubMedPubMedCentral

42.

Doughari HJ, Ndakidemi PA, Human IS, et al. The ecology, biology and pathogenesis of Acinetobacter spp.: an overview. Microbes Environ. 2011;26(2):101–12. https://doi.org/10.1264/jsme2.me10179.CrossRefPubMed

43.

Wei AL, Li M, Li GQ, et al. Oral microbiome and pancreatic cancer. World J Gastroenterol. 2020;26(48):7679–92. https://doi.org/10.3748/wjg.v26.i48.7679.CrossRefPubMedPubMedCentral

44.

Lu H, Ren Z, Li A, et al. Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls. J Oral Microbiol. 2019;11(1):1563409. https://doi.org/10.1080/20002297.2018.1563409.CrossRefPubMedPubMedCentral

45.

Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368(6494):973–80. https://doi.org/10.1126/science.aay9189.CrossRefPubMedPubMedCentral

46.

Kartal E, Schmidt TSB, Molina-Montes E, et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut. 2022;71(7):1359–72. https://doi.org/10.1136/gutjnl-2021-324755.CrossRefPubMed

Title: Heterogeneous changes in gut and tumor microbiota in patients with pancreatic cancer: insights from clinical evidence
Authors: Feng Zhao
Anli Chen
Xiaotian Wu
Xiangyu Deng
Jiali Yang
Jianjiang Xue
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Pancreatic Cancer
Pancreatic Cancer
Cancer Biomarker
Chronic Pancreatitis
Respiratory Microbiota
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12202-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer

The role of adjuvant transcatheter arterial chemoembolization following repeated curative resection/ablation for hepatocellular carcinoma with early recurrence: a propensity score matching analysis

Protect the recurrent laryngeal nerves in US-guided microwave ablation of thyroid nodules at Zuckerkandl tubercle: a pilot study

Assessing the genomic feature of Chinese patients with ampullary adenocarcinoma: potential therapeutic targets

The incidence of early onset colorectal cancer in Aotearoa New Zealand: 2000–2020

Keynote webinar | Spotlight on antibody–drug conjugates in cancer